First-line afatinib for advanced EGFR mutation-positive (EGFRm plus ) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials
第一作者机构:[1]Univ Duisburg Essen, West German Canc Ctr, Univ Hosp Essen,Dept Med Oncol, Essen, Germany;[2]Partner Site Univ Hosp Essen, German Canc Consortium DKTK, Essen, Germany;
推荐引用方式(GB/T 7714):
Schuler M.,Paz-Ares L.,Sequist L. V.,et al.First-line afatinib for advanced EGFR mutation-positive (EGFRm plus ) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials[J].EUROPEAN JOURNAL OF CANCER.2017,72:S176-S177.
APA:
Schuler, M.,Paz-Ares, L.,Sequist, L. V.,Tan, E. H.,Mok, T....&Yang, J. C. H..(2017).First-line afatinib for advanced EGFR mutation-positive (EGFRm plus ) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials.EUROPEAN JOURNAL OF CANCER,72,
MLA:
Schuler, M.,et al."First-line afatinib for advanced EGFR mutation-positive (EGFRm plus ) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials".EUROPEAN JOURNAL OF CANCER 72.(2017):S176-S177